Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations

Evofem Biosciences, Inc.

2025-Q2 EPS reported -$0.01 revenue$5,670,000

Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.
Loss from operations improved to $1.3M in Q2 2025 versus $1.4M in the prior year quarter.
Raised $2.4M net in April and June 2025 from sale of senior subordinated notes and warrants to Aditxt (ADTX).
PHEXXI submitted for UAE marketing approval by licensee Pharma 1; SOLOSEC submission expected Q3 2025.
Net loss per share was $(0.02) in Q2 2025 vs net income of $0.02 per share in Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.